Joel Isaacson & Co. LLC increased its holdings in CVS Health Corporation (NYSE:CVS) by 0.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 44,425 shares of the pharmacy operator’s stock after buying an additional 3 shares during the quarter. CVS Health Corporation comprises approximately 0.7% of Joel Isaacson & Co. LLC’s investment portfolio, making the stock its 17th largest holding. Joel Isaacson & Co. LLC’s holdings in CVS Health Corporation were worth $3,574,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. CGOV Asset Management grew its stake in shares of CVS Health Corporation by 0.3% during the 1st quarter. CGOV Asset Management now owns 1,148,337 shares of the pharmacy operator’s stock worth $120,090,000 after purchasing an additional 3,466 shares during the period. Waldron LP grew its stake in shares of CVS Health Corporation by 217.4% during the 1st quarter. Waldron LP now owns 10,633 shares of the pharmacy operator’s stock worth $835,000 after purchasing an additional 7,283 shares during the period. YCG LLC grew its stake in shares of CVS Health Corporation by 21.5% during the 1st quarter. YCG LLC now owns 79,707 shares of the pharmacy operator’s stock worth $6,257,000 after purchasing an additional 14,123 shares during the period. DUPONT CAPITAL MANAGEMENT Corp grew its stake in shares of CVS Health Corporation by 125.4% during the 1st quarter. DUPONT CAPITAL MANAGEMENT Corp now owns 281,005 shares of the pharmacy operator’s stock worth $22,059,000 after purchasing an additional 156,338 shares during the period. Finally, Mercer Capital Advisers Inc. acquired a new stake in shares of CVS Health Corporation during the 1st quarter worth approximately $118,000. Institutional investors own 81.51% of the company’s stock.

In other news, EVP Thomas M. Moriarty sold 20,547 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $81.17, for a total value of $1,667,799.99. Following the sale, the executive vice president now directly owns 43,178 shares in the company, valued at $3,504,758.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO David M. Denton sold 237,078 shares of the company’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $79.65, for a total value of $18,883,262.70. Following the completion of the sale, the chief financial officer now owns 141,096 shares in the company, valued at $11,238,296.40. The disclosure for this sale can be found here. Insiders sold 716,625 shares of company stock worth $58,318,431 in the last three months. 0.61% of the stock is owned by corporate insiders.

A number of equities research analysts have recently commented on the stock. Royal Bank Of Canada assumed coverage on shares of CVS Health Corporation in a research note on Tuesday, September 19th. They set an “outperform” rating and a $95.00 price objective on the stock. Jefferies Group LLC raised their price objective on shares of CVS Health Corporation from $82.00 to $86.00 and gave the stock a “hold” rating in a research note on Friday, September 15th. Needham & Company LLC assumed coverage on shares of CVS Health Corporation in a research note on Tuesday, June 27th. They set a “hold” rating on the stock. Guggenheim reaffirmed a “buy” rating on shares of CVS Health Corporation in a research note on Monday, July 3rd. Finally, Leerink Swann set a $90.00 price objective on shares of CVS Health Corporation and gave the stock a “buy” rating in a research note on Tuesday, June 27th. One analyst has rated the stock with a sell rating, eight have given a hold rating and sixteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $90.23.

CVS Health Corporation (NYSE:CVS) last posted its earnings results on Tuesday, August 8th. The pharmacy operator reported $1.33 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.31 by $0.02. The company had revenue of $45.69 billion for the quarter, compared to analyst estimates of $45.36 billion. CVS Health Corporation had a return on equity of 17.47% and a net margin of 2.93%. CVS Health Corporation’s revenue was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.32 earnings per share.

The company also recently announced a quarterly dividend, which will be paid on Friday, November 3rd. Shareholders of record on Tuesday, October 24th will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 2.71%. The ex-dividend date of this dividend is Monday, October 23rd. CVS Health Corporation’s dividend payout ratio (DPR) is 39.92%.

ILLEGAL ACTIVITY WARNING: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/10/13/joel-isaacson-co-llc-raises-position-in-cvs-health-corporation-cvs.html.

About CVS Health Corporation

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Institutional Ownership by Quarter for CVS Health Corporation (NYSE:CVS)

Receive News & Stock Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related stocks with our FREE daily email newsletter.